What the AMC tests here
Questions in this area come in two kinds. Screening questions give an asymptomatic woman and a test result, and ask what to do next: repeat in five years, repeat in 12 months, refer to colposcopy or something else. Symptom questions give a woman with bleeding, a pelvic mass, a vulval lesion or a breast lump, and ask for the most appropriate investigation or referral.
The most common error is mixing the two. Screening is for people without symptoms. A woman with postcoital bleeding, postmenopausal bleeding or a breast lump needs diagnostic assessment, not a screening test. The AMC places screening options next to diagnostic ones to see whether you can tell the difference.
Australian screening programs differ from those in many other countries. Cervical screening is a primary HPV test every five years from 25 to 74, with self-collection available to everyone eligible. Breast screening invites women aged 50 to 74 for two-yearly mammograms. There is no screening program for ovarian or endometrial cancer.
- Screening: asymptomatic, follow the program pathway
- Symptoms: investigate and refer, regardless of screening history
- Lead-ins: next step, most appropriate investigation, most appropriate referral, correct advice
The National Cervical Screening Program
Since 2017, Australia has used a five-yearly cervical screening test that detects oncogenic HPV, replacing the two-yearly Pap smear. Women and people with a cervix aged 25 to 74 who have ever been sexually active are eligible, including those who have been vaccinated against HPV. People aged 70 to 74 with a negative HPV result can exit the program. Since July 2022, everyone eligible can choose to collect their own vaginal sample, which is tested for HPV only and is as accurate as a clinician-collected sample for HPV detection.
The next step depends on the HPV result. HPV not detected means return in five years. HPV 16 or 18 detected means direct referral for colposcopy, whatever the cytology shows. Oncogenic HPV other than 16 or 18 needs liquid-based cytology (LBC): this is done on the same sample if a clinician collected it, or a clinician-collected sample is needed if the person self-collected. If the LBC is negative or low grade, the person is at intermediate risk and has a repeat HPV test in 12 months. If the LBC shows a possible or definite high-grade lesion, refer to colposcopy.
At the 12-month repeat, HPV not detected returns the person to five-yearly screening, while persistent HPV leads to colposcopy. Some higher-risk groups go to colposcopy sooner rather than waiting 12 months, so follow the guideline for people who are overdue for screening or immune-deficient. Immune-deficient people are screened every three years. The 2025 guideline update made changes to follow-up after treatment: people treated for high-grade lesions have annual HPV tests (test of cure) until two consecutive negative results, then return to routine screening.
- Age 25 to 74, every 5 years, HPV test
- Self-collection available to all eligible people; it tests for HPV only
- HPV 16/18: colposcopy
- Other oncogenic HPV plus negative or low-grade LBC: repeat HPV in 12 months
- Other oncogenic HPV plus high-grade LBC: colposcopy
- Immune-deficient: 3-yearly screening
- Screening can be done in pregnancy; vaccinated people still screen
Cervical cancer and symptomatic women
Cervical cancer is caused by persistent oncogenic HPV infection. Most cases in Australia now occur in people who are under-screened or have never been screened. Early cancer may be asymptomatic. Symptoms include postcoital bleeding, intermenstrual bleeding, postmenopausal bleeding, unusual discharge and, later, pelvic pain or symptoms of local spread.
Symptomatic women do not follow the screening pathway. A woman with abnormal bleeding should have a speculum examination to look at the cervix and a co-test (HPV and LBC) collected by a clinician, not a self-collected sample. A visible suspicious lesion needs urgent referral to a gynaecologist or gynaecological oncologist regardless of test results. Persistent unexplained postcoital bleeding needs referral even if tests are normal.
Treatment depends on stage: early disease is treated with surgery, and more advanced disease with chemoradiation. Australia has a national strategy to eliminate cervical cancer as a public health problem by 2035, based on HPV vaccination through the school program, five-yearly HPV screening with self-collection, and treatment. The HPV vaccine is given as a single dose in the school program, at around 12 to 13 years.
- Postcoital bleeding: speculum, clinician-collected co-test, refer if persistent or a lesion is seen
- Visible cervical lesion: refer urgently, even if the screening test was normal
- Never-screened women: higher risk; encourage screening, including self-collection
- HPV vaccination: single dose in the school program
Endometrial, ovarian and vulval cancer
Endometrial cancer typically presents with postmenopausal bleeding, which is never normal and must be investigated. Risk factors relate to unopposed oestrogen: obesity, PCOS with long anovulatory cycles, nulliparity, late menopause, oestrogen-only therapy in a woman with a uterus, tamoxifen and Lynch syndrome. Diabetes and hypertension also raise risk. The first investigation for postmenopausal bleeding is transvaginal ultrasound to measure endometrial thickness. A thickened endometrium (more than 4 mm in a woman not on MHT is a commonly used threshold), or persistent bleeding even with a thin endometrium, needs hysteroscopy and endometrial biopsy. Treatment is usually total hysterectomy and bilateral salpingo-oophorectomy.
Ovarian cancer often presents late with vague, persistent symptoms: abdominal bloating or distension, early satiety, pelvic or abdominal pain, urinary frequency and change in bowel habit. A woman with these symptoms that are new and persistent, especially over 50, should have a pelvic ultrasound (transvaginal and transabdominal) and a serum CA-125. A complex mass, ascites or a raised CA-125 in a postmenopausal woman needs urgent referral to a gynaecological oncologist. There is no effective screening test for ovarian cancer in average-risk women, so CA-125 and ultrasound screening are wrong answers for an asymptomatic woman. Women with BRCA1 or BRCA2 pathogenic variants are offered risk-reducing salpingo-oophorectomy after childbearing, at an age that depends on the gene.
Vulval cancer mainly affects older women. It presents with persistent itch, a lump or ulcer, bleeding or pain. Lichen sclerosus (white, atrophic skin with loss of architecture) increases the risk and is treated with a potent topical corticosteroid and long-term review. Any persistent or suspicious vulval lesion needs a biopsy. A new Bartholin gland mass in an older woman also needs biopsy.
- Postmenopausal bleeding: transvaginal ultrasound, then hysteroscopy and biopsy if thickened or persistent
- Tamoxifen: increases endometrial cancer risk; investigate any bleeding
- Persistent bloating and early satiety over 50: ultrasound and CA-125
- No ovarian cancer screening for average-risk women
- Lichen sclerosus: potent topical steroid, long-term follow-up, biopsy suspicious areas
- Lynch syndrome: risk of endometrial, ovarian and colorectal cancer
Breast screening, familial risk and breast lumps
BreastScreen Australia actively invites women aged 50 to 74 for a free mammogram every two years. Women aged 40 to 49 and 75 and over are eligible to attend but are not actively invited. Screening is for women without symptoms. A woman with a breast lump, skin change or nipple change needs diagnostic assessment through her GP, not a screening appointment.
Familial risk is assessed using family history: the number of affected relatives, their age at diagnosis, ovarian cancer in the family, male breast cancer, Ashkenazi Jewish ancestry and known gene variants. Most women with a family history are at or slightly above average risk and follow population screening. Women at high risk are referred to a family cancer clinic for genetic testing and may have earlier and more intensive surveillance, including MRI. Cancer Australia and eviQ provide Australian risk categories.
The triple test is the standard for investigating any breast lump: clinical examination, imaging and non-surgical biopsy (usually core biopsy). Under 35, ultrasound is the first imaging test because breast tissue is dense. From 35, use mammography plus ultrasound. The lump is considered benign only if all three components are benign. Common benign conditions include fibroadenoma (mobile, firm, young women), cysts (smooth, often around menopause, aspirated if symptomatic), fat necrosis (after trauma), duct ectasia and intraductal papilloma (bloody nipple discharge). Breast cancer can present as a hard irregular lump, skin dimpling, nipple inversion, peau d'orange, eczema-like change of the nipple (Paget disease) or an inflamed breast that does not settle with antibiotics (inflammatory breast cancer).
- BreastScreen: invited 50–74, two-yearly; eligible from 40
- Symptomatic women: diagnostic imaging, not BreastScreen
- Triple test: examination, imaging, core biopsy
- Under 35: ultrasound first; 35 and over: mammogram plus ultrasound
- Nipple eczema not responding to treatment: biopsy for Paget disease
- Mastitis in a non-lactating woman that does not settle: triple test
Australian differences to know
Overseas-trained doctors often answer from older Pap smear rules or from programs in their home country. Use the Australian rules below in the exam.
- Cervical screening: HPV test every 5 years from 25 to 74, not 3-yearly cytology
- Self-collection available to every eligible person, not only under-screened people
- HPV 16/18 goes straight to colposcopy
- Elimination target for cervical cancer by 2035
- Single-dose HPV vaccine in the school program
- BreastScreen invites women 50–74 every two years
- No ovarian or endometrial cancer screening program
How to approach screening and cancer stems
Ask first: does she have symptoms? If yes, investigate and refer; ignore the screening interval. If no, find her age, the last screening result and any risk group, then follow the program pathway exactly.
For cervical results, read the HPV type first, then the cytology. For bleeding after menopause, think endometrial cancer and start with transvaginal ultrasound. For a pelvic mass, check menopausal status, ultrasound features and CA-125. For a breast lump, apply the triple test with the age-appropriate imaging.
- Asymptomatic with normal HPV 3 years ago: next test in 2 years, not now
- Postcoital bleeding at 32 with negative HPV last year: speculum and co-test, refer if persistent
- Bleeding on tamoxifen: transvaginal ultrasound and hysteroscopy
- Breast lump at 28: ultrasound and biopsy if needed, not mammogram first
| Situation | Finding | Next step |
|---|---|---|
| Routine cervical screen | HPV not detected | Repeat in 5 years |
| Routine cervical screen | HPV 16/18 detected | Refer for colposcopy |
| Routine cervical screen | Other HPV, LBC negative or low grade | Repeat HPV in 12 months |
| Routine cervical screen | Other HPV, LBC high grade | Refer for colposcopy |
| Self-collected sample | Other HPV detected | Clinician-collected LBC |
| Postcoital bleeding | Any screening history | Speculum, clinician co-test, refer if persistent or lesion seen |
| Postmenopausal bleeding | Endometrium thickened | Hysteroscopy and endometrial biopsy |
| Bloating and early satiety, age 58 | Persistent new symptoms | Pelvic ultrasound and CA-125 |
| Breast lump, age 28 | Mobile smooth lump | Triple test with ultrasound first |
| Asymptomatic woman, 52 | Due for breast screening | BreastScreen mammogram, two-yearly |
Worked examples in AMC style
Pick an answer to see why each option is right or wrong. These examples are written for this page; the bank holds the full set for cervical screening & gynae cancers.
Example 1
A 34-year-old woman has a routine clinician-collected cervical screening test. The result shows oncogenic HPV (not 16/18) detected, with liquid-based cytology reported as low-grade squamous intraepithelial lesion (LSIL). Her previous screen five years ago was normal. She is well and has no symptoms.
What is the most appropriate next step?
-
Colposcopy is for HPV 16/18 or high-grade cytology, not other HPV with low-grade changes on a first result.
-
Other oncogenic HPV with negative or low-grade cytology is intermediate risk. Repeat the HPV test in 12 months; most infections clear.
-
An HPV-positive result cannot be managed as routine.
-
Six-monthly cytology is from the old Pap smear program.
-
Treatment without colposcopic assessment and histology is not indicated.
Show answer and reasoning
Answer: B. Repeat the HPV test in 12 months' time
- A. Colposcopy is for HPV 16/18 or high-grade cytology, not other HPV with low-grade changes on a first result.
- B. Other oncogenic HPV with negative or low-grade cytology is intermediate risk. Repeat the HPV test in 12 months; most infections clear.
- C. An HPV-positive result cannot be managed as routine.
- D. Six-monthly cytology is from the old Pap smear program.
- E. Treatment without colposcopic assessment and histology is not indicated.
Non-16/18 HPV with negative or low-grade LBC: repeat HPV in 12 months.
Based on: National Cervical Screening Program clinical guidelines
Example 2
A 61-year-old woman has had two episodes of light vaginal bleeding in the past month. Her menopause was at 52 and she has never used MHT. She takes tamoxifen after treatment for breast cancer two years ago. Her BMI is 34 kg/m2. Speculum examination shows a normal cervix and her cervical screening test last year was negative.
What is the most appropriate next step?
-
Cervical screening does not assess the endometrium; postmenopausal bleeding must be investigated.
-
Stopping tamoxifen is an oncology decision and does not investigate the bleeding.
-
Treating presumed atrophy without excluding cancer is unsafe.
-
Postmenopausal bleeding with tamoxifen and obesity raises the risk of endometrial cancer. Transvaginal ultrasound is the first step, followed by hysteroscopy and biopsy; with tamoxifen, many units go straight to hysteroscopy.
-
CA-125 is for suspected ovarian cancer and is not the test for postmenopausal bleeding.
Show answer and reasoning
Answer: D. Transvaginal ultrasound of the endometrium
- A. Cervical screening does not assess the endometrium; postmenopausal bleeding must be investigated.
- B. Stopping tamoxifen is an oncology decision and does not investigate the bleeding.
- C. Treating presumed atrophy without excluding cancer is unsafe.
- D. Postmenopausal bleeding with tamoxifen and obesity raises the risk of endometrial cancer. Transvaginal ultrasound is the first step, followed by hysteroscopy and biopsy; with tamoxifen, many units go straight to hysteroscopy.
- E. CA-125 is for suspected ovarian cancer and is not the test for postmenopausal bleeding.
Postmenopausal bleeding is never normal: transvaginal ultrasound, then hysteroscopy and biopsy.
Based on: Cancer Council optimal care pathway for endometrial cancer; RANZCOG guidance
Example 3
A 27-year-old woman presents with a 2 cm smooth, mobile, non-tender lump in the upper outer quadrant of her right breast, noticed 3 weeks ago. It has not changed through her cycle. There is no nipple discharge or skin change. She has no family history of breast or ovarian cancer.
What is the most appropriate next step?
-
Mammography is less useful in dense young breasts, and screening is not for symptomatic women.
-
Under 35, ultrasound is the first imaging test in the triple test, with core biopsy if the lump is not clearly a simple cyst.
-
It is probably a fibroadenoma, but the diagnosis needs the triple test.
-
Excision is not the first step and is often unnecessary for confirmed fibroadenomas.
-
The lump has persisted through a cycle already; it needs imaging now.
Show answer and reasoning
Answer: B. Breast ultrasound, biopsy if needed
- A. Mammography is less useful in dense young breasts, and screening is not for symptomatic women.
- B. Under 35, ultrasound is the first imaging test in the triple test, with core biopsy if the lump is not clearly a simple cyst.
- C. It is probably a fibroadenoma, but the diagnosis needs the triple test.
- D. Excision is not the first step and is often unnecessary for confirmed fibroadenomas.
- E. The lump has persisted through a cycle already; it needs imaging now.
Breast lump under 35: triple test starting with ultrasound.
Based on: Cancer Australia: Investigation of a new breast symptom
Quick recall
Tap a card to turn it over. If you can answer all eight without looking, move on to timed questions.
Where candidates lose marks
- Screening a symptomatic woman
Bleeding or a lump needs diagnostic investigation and referral, not a screening test.
- Old Pap smear rules
Two-yearly cytology and starting at 18 no longer apply in Australia.
- Screening for ovarian cancer
CA-125 and ultrasound are not used for average-risk women without symptoms.
- Mammogram first under 35
Ultrasound is the first-line imaging for young women.
- Self-collection for symptoms
Symptomatic women need a clinician-collected co-test and examination.
How to study cervical screening & gynae cancers
Day 1: The NCSP pathway; draw the HPV result flowchart from memory and practise 10 result scenarios.
Day 2: Cervical cancer, symptomatic women, HPV vaccination and the 2035 elimination strategy.
Day 3: Endometrial cancer and postmenopausal bleeding; ovarian masses and CA-125; BRCA and Lynch.
Day 4: Vulval disease and cancer; then breast screening, familial risk and the triple test.
Day 5: 25 mixed questions; check each wrong answer against the table on this page.
Sources and further reading
Check the current edition of each guideline before your exam. This page is study material, not clinical advice.
- National Cervical Screening Program: Clinical guidelines (Cancer Council Australia)
- Australian Government: National Cervical Screening Program
- Australian Government: Update to NCSP guidelines fact sheet (2025)
- BreastScreen Australia
- Cancer Australia: Investigation of a new breast symptom
- Cancer Council: Optimal care pathways for gynaecological cancers
- eviQ: Cancer genetics risk management